| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | endopeptidase activity | 5.12e-04 | 430 | 8 | 3 | GO:0004175 | |
| GeneOntologyMolecularFunction | peptidase activity | 1.73e-03 | 654 | 8 | 3 | GO:0008233 | |
| GeneOntologyMolecularFunction | serine-type endopeptidase activity | 2.43e-03 | 190 | 8 | 2 | GO:0004252 | |
| GeneOntologyMolecularFunction | serine-type peptidase activity | 2.87e-03 | 207 | 8 | 2 | GO:0008236 | |
| GeneOntologyMolecularFunction | serine hydrolase activity | 3.01e-03 | 212 | 8 | 2 | GO:0017171 | |
| MousePheno | sternebra fusion | 1.75e-05 | 19 | 5 | 2 | MP:0010082 | |
| MousePheno | abnormal sternebra morphology | 1.35e-04 | 52 | 5 | 2 | MP:0004322 | |
| MousePheno | liver hypoplasia | 1.92e-04 | 62 | 5 | 2 | MP:0000600 | |
| MousePheno | abnormal liver size | 6.08e-04 | 562 | 5 | 3 | MP:0004848 | |
| MousePheno | short snout | 9.22e-04 | 136 | 5 | 2 | MP:0000445 | |
| MousePheno | small snout | 1.03e-03 | 144 | 5 | 2 | MP:0030190 | |
| MousePheno | abnormal placenta vasculature | 1.83e-03 | 192 | 5 | 2 | MP:0003231 | |
| MousePheno | increased malignant tumor incidence | 2.77e-03 | 237 | 5 | 2 | MP:0002018 | |
| MousePheno | enlarged liver | 3.15e-03 | 253 | 5 | 2 | MP:0000599 | |
| MousePheno | abnormal sternum morphology | 3.20e-03 | 255 | 5 | 2 | MP:0000157 | |
| MousePheno | abnormal snout morphology | 3.25e-03 | 257 | 5 | 2 | MP:0000443 | |
| MousePheno | lethality throughout fetal growth and development, complete penetrance | 3.40e-03 | 263 | 5 | 2 | MP:0011099 | |
| MousePheno | reduced female fertility | 4.28e-03 | 296 | 5 | 2 | MP:0001923 | |
| MousePheno | abnormal pectoral girdle bone morphology | 4.43e-03 | 301 | 5 | 2 | MP:0004508 | |
| MousePheno | small liver | 4.84e-03 | 315 | 5 | 2 | MP:0000601 | |
| Pubmed | HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. | 1.30e-06 | 8 | 8 | 2 | 23934123 | |
| Pubmed | 4.36e-05 | 44 | 8 | 2 | 23070814 | ||
| ToppCell | Hippocampus-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Excitatory_Neuron.Slc17a7.Rgs14_(CA2_Principal_cells)|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 6.08e-05 | 67 | 8 | 2 | 771fc7c4917b5dc5ebf1b7be304d62902f0b75cc | |
| ToppCell | Hippocampus-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Excitatory_Neuron.Slc17a7.Rgs14_(CA2_Principal_cells)-|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 6.08e-05 | 67 | 8 | 2 | f56d8787ab2170997d28a2f66d83b4c18362b97d | |
| ToppCell | TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Muscle_invasive_urothelial_carcinoma-6|TCGA-Bladder / Sample_Type by Project: Shred V9 | 1.28e-04 | 97 | 8 | 2 | 833f2e02ae10d4b021404bd893c06ef308ca5a7a | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.01e-04 | 149 | 8 | 2 | 54c9c6282f5f5de43dfaf2972fab3e3dcf9838a3 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.01e-04 | 149 | 8 | 2 | 14d2e8cab97108d8fa94e540c1957b73ed32dc73 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 3.05e-04 | 150 | 8 | 2 | 8645b9c7f9511ed6cc9afe04440c2873a3094150 | |
| ToppCell | TCGA-Thryoid-Primary_Tumor-Thyroid_Papillary_Carcinoma-Tall_Cell-1|TCGA-Thryoid / Sample_Type by Project: Shred V9 | 3.30e-04 | 156 | 8 | 2 | 45a05c7a45a3ec8551818ab67f18b3b9553934c1 | |
| ToppCell | facs-Heart-Unknown-3m-Myeloid-monocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.34e-04 | 157 | 8 | 2 | 8a393eece90fb9a1b7c356736bdb36277261fbd3 | |
| ToppCell | PBMC-Severe-Myeloid-cDC-cDC-cDC_4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.34e-04 | 157 | 8 | 2 | f896997490bb2eec598c6581f161220e70f9a991 | |
| ToppCell | facs-Heart-Unknown-3m-Myeloid|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.34e-04 | 157 | 8 | 2 | 2ac4695d9e4ca8d4ba19c555e9a1d86ac8f398ab | |
| ToppCell | facs-Heart-Unknown-3m-Myeloid-monocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.34e-04 | 157 | 8 | 2 | 8d30d8e6fae93afcada6bd68799439335cd65b69 | |
| ToppCell | PBMC-Severe-Myeloid-cDC-cDC-cDC_4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 3.34e-04 | 157 | 8 | 2 | 14a8516346a89a89f1119b744625bd9844a74a03 | |
| ToppCell | PND10-Immune-Immune_Myeloid-DC-cDC1-cDC1_mature|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.43e-04 | 159 | 8 | 2 | 807ee55fe0d3645fbfb98f641dd0a0555b847cf5 | |
| ToppCell | TCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Oligodendroglioma|TCGA-Brain / Sample_Type by Project: Shred V9 | 3.51e-04 | 161 | 8 | 2 | 5f6b2d7f80a8ee16651e304481d2da3fae313824 | |
| ToppCell | kidney_cells-Adult_normal_reference-Mesenchymal--glomerular_mesenchymal_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 3.56e-04 | 162 | 8 | 2 | f1851a173d3bcca2981d934161ec85d1cc0af5a2 | |
| ToppCell | kidney_cells-Adult_normal_reference-Mesenchymal--glomerular_mesenchymal_cell-Renin-positive_Juxtaglomerular_Granular_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 3.56e-04 | 162 | 8 | 2 | c7114e24cb5525abb9780ca3d35dbcc4eabd4b64 | |
| ToppCell | kidney_cells-Adult_normal_reference-Mesenchymal-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 3.56e-04 | 162 | 8 | 2 | 5d902bb31e691aea9749617cc88303c2448f24b8 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal--glomerular_mesenchymal_cell-Renin-positive_Juxtaglomerular_Granular_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.64e-04 | 164 | 8 | 2 | 43630a448f4369fa9e4e3eccdf3b9f29cec16c39 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal--glomerular_mesenchymal_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.64e-04 | 164 | 8 | 2 | 46208f18325976c89f572f6627aea0582142b92d | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.64e-04 | 164 | 8 | 2 | 108fbecb56d69a675d6ce6e826a873ae528f2fd7 | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Stem_cells-neuroepithelial-like_cells|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type. | 3.78e-04 | 167 | 8 | 2 | e488d9c7cf4355959e3833de3bd496c13fc11b1b | |
| ToppCell | Control-B_cells-Activated_B_cells|Control / group, cell type (main and fine annotations) | 3.82e-04 | 168 | 8 | 2 | a7159a35fe37f8c241cf8d391debe271e0698105 | |
| ToppCell | PCW_05-06-Neuronal-Neuronal_SCP-neuro_proliferating_SCP3_(1)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 3.87e-04 | 169 | 8 | 2 | d9c3b22f62b882b8a2ea6fd9cf7afbe6d1775745 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal--glomerular_mesenchymal_cell-Renin-positive_Juxtaglomerular_Granular_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 3.92e-04 | 170 | 8 | 2 | 99dd734c0972a40d5381e8e2d96bdaa31f6d06e6 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal--glomerular_mesenchymal_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 3.92e-04 | 170 | 8 | 2 | 3a14eeae221b8bb0bd0dadcb8e7a603431240a1e | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)-Glut_IT_L5/L6_Car3_THEMIS-Exc_L5-6_THEMIS_IL7R|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.92e-04 | 170 | 8 | 2 | 6af7dee9b8298d4499e05a82cf9cdfe3bd81d384 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 3.92e-04 | 170 | 8 | 2 | cdb6fad277f284c3fd5a6f45672a8edc24715882 | |
| ToppCell | 3'-GW_trimst-1.5-SmallIntestine-Neuronal-Glial_immature-ENCC/glia_Progenitor|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.05e-04 | 173 | 8 | 2 | 23e50492bc673aff9df95d97f0b9be4ce57cbf01 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)-Glut_IT_L5/L6_Car3_THEMIS-Exc_L5-6_THEMIS_GPR21|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.10e-04 | 174 | 8 | 2 | 0df738309b7b6e77675ea74e7a87e66601b0073d | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)-Glut_IT_L5/L6_Car3_THEMIS-Exc_L5-6_THEMIS_THTPA|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.20e-04 | 176 | 8 | 2 | e788c7e0b2bfde31fddbf9e04d07140f8b964857 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)-Glut_IT_L5/L6_Car3_THEMIS|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.24e-04 | 177 | 8 | 2 | 64fbf799e7b0c4003b2f486cc41b0f7e7c11ea0c | |
| ToppCell | PCW_05-06-Neuronal-Neuronal_SCP-neuro_pre_proliferating_SCP_(4)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.24e-04 | 177 | 8 | 2 | 59726bfd98f656fdcedf448a7e2e76a9bfad8285 | |
| ToppCell | PBMC-Control-Myeloid-cDC-cDC-cDC_12|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.24e-04 | 177 | 8 | 2 | cbedac0bddb8fc330a464815c905928c553b0fc0 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)-Glut_IT_L5/L6_Car3_THEMIS-Exc_L5-6_THEMIS_THTPA|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.29e-04 | 178 | 8 | 2 | e4e11e4940c911c17806200c25096928153c684d | |
| ToppCell | TCGA-Skin-Metastatic-Melanoma-Skin_Cutaneous_Melanoma-5|TCGA-Skin / Sample_Type by Project: Shred V9 | 4.29e-04 | 178 | 8 | 2 | ad5cd505ca1cef8ac29b2af7e2c3e01ebc140c14 | |
| ToppCell | PBMC-Control-Myeloid-cDC-cDC-cDC_12|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.29e-04 | 178 | 8 | 2 | 04bfecf5ea5d85c843e48d08718b5d69e7bf834e | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)-Glut_IT_L5/L6_Car3_THEMIS|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.29e-04 | 178 | 8 | 2 | a62137d7f5fac16619f8a02844cdb0be7a794bf2 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.29e-04 | 178 | 8 | 2 | f94e306b9550f3d1b5de0bb806790c17823d439e | |
| ToppCell | droplet-Liver-LIVER_HEP|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.39e-04 | 180 | 8 | 2 | 423454e3390080ae03bb3cbb267255ebfe4df080 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.39e-04 | 180 | 8 | 2 | dd1b10c7f5a0fbc63163844ca1882884a24a84d3 | |
| ToppCell | PCW_05-06-Neuronal-Neuronal_SCP|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.48e-04 | 182 | 8 | 2 | b4fc5e4f5d8440a3c9ee0a6fd0da87b43cabc8c6 | |
| ToppCell | TCGA-Thryoid-Primary_Tumor-Thyroid_Papillary_Carcinoma-Classical-1|TCGA-Thryoid / Sample_Type by Project: Shred V9 | 4.53e-04 | 183 | 8 | 2 | 06e4b05d86a7d643569e19575c2c9aa351d33f29 | |
| ToppCell | PCW_05-06-Neuronal-Neuronal_SCP-neuro_SCP_(0)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.53e-04 | 183 | 8 | 2 | f517215ff45dec914af52dfdbc4579c19654c3aa | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.63e-04 | 185 | 8 | 2 | 16e9ccea0e3b95d90dc48ef74206c805681dac0b | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.63e-04 | 185 | 8 | 2 | f1263899a2d41d182022dc4ca62cbae08a463c89 | |
| ToppCell | facs-Trachea-18m-Mesenchymal-fibroblast-fibroblast_of_trachea-|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.68e-04 | 186 | 8 | 2 | bdc87e4631a8ea73e262e541aa84a28f24c94b00 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Lymphocytic|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.68e-04 | 186 | 8 | 2 | bbcd9062c0f6f65ca6f3cb101b6fa72ddd1e14fe | |
| ToppCell | facs-Lung-18m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.78e-04 | 188 | 8 | 2 | bba6b273bd47dd0e27fde914e9e6fc9d76fd5176 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.94e-04 | 191 | 8 | 2 | b7d17d3ba488378b30f3732f8109f4a7c1673e61 | |
| ToppCell | wk_08-11-Mesenchymal-Fibroblast-Mesenchymal_3|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 4.99e-04 | 192 | 8 | 2 | d88753b200d9c8da6716222d697ddf0a1548d6c8 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.99e-04 | 192 | 8 | 2 | 89b8ebdc285ed3c0f807fd1157271130d37dfa41 | |
| ToppCell | COVID-19_Mild-Lymphoid_B-B_intermediate|COVID-19_Mild / Disease group, lineage and cell class | 5.09e-04 | 194 | 8 | 2 | bf6f72a489c62cbf1a679552d8c5eaaaa0b99d33 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.14e-04 | 195 | 8 | 2 | 7796ea9247f4c63762f0de8490fed08b9717fa23 | |
| ToppCell | droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.14e-04 | 195 | 8 | 2 | 3e519cffa6144a62b06124642a14c9ff39b76554 | |
| ToppCell | Tracheal-10x5prime-Stromal-Schwann|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.20e-04 | 196 | 8 | 2 | b6226163d9fc93ecfff2115bb74408303a000490 | |
| ToppCell | Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_peribronchial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.30e-04 | 198 | 8 | 2 | 300d7cc56207d77168390fa1ffcbcf76767b1b80 | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-B-B_intermediate|COVID-19_Mild / Disease, condition lineage and cell class | 5.36e-04 | 199 | 8 | 2 | 1c6a08d01f6c1a2a4b6587d3a4522efbd03275e1 | |
| ToppCell | severe-B_intermediate|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.36e-04 | 199 | 8 | 2 | 17283d75a2a900369f63ed02996e7ede97f46140 | |
| ToppCell | Sepsis-Int-URO-Lymphocyte-B-B_intermediate|Int-URO / Disease, condition lineage and cell class | 5.41e-04 | 200 | 8 | 2 | 221dd8d8851c47f2202ba848de3a041b17b1db3f | |
| ToppCell | mild-B_intermediate|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.41e-04 | 200 | 8 | 2 | fe815824e9e4be3f3db73610e3814a7fd533da65 | |
| ToppCell | severe-B_intermediate|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.41e-04 | 200 | 8 | 2 | 6d0ac3d00400dd5657ee266f7b885381bf790ce1 | |
| ToppCell | mild-B_intermediate|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.41e-04 | 200 | 8 | 2 | 8e3132a1fe3708f725c5c4077878fb87bbea3678 | |
| Drug | Propafenone hydrochloride [34183-22-7]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 3.25e-05 | 193 | 8 | 3 | 5437_UP | |
| Drug | rofecoxib; Up 200; 10uM; MCF7; HG-U133A | 3.46e-05 | 197 | 8 | 3 | 205_UP | |
| Drug | Clemizole hydrochloride [1163-36-6]; Up 200; 11uM; PC3; HT_HG-U133A | 3.46e-05 | 197 | 8 | 3 | 3672_UP | |
| Drug | Indapamide [26807-65-8]; Up 200; 10.6uM; PC3; HT_HG-U133A | 3.51e-05 | 198 | 8 | 3 | 3778_UP | |
| Drug | Luteolin [491-70-3]; Up 200; 14uM; PC3; HT_HG-U133A | 3.57e-05 | 199 | 8 | 3 | 6658_UP | |
| Drug | AC1O745K | 1.31e-04 | 50 | 8 | 2 | CID006518178 | |
| Drug | chlorate | 5.58e-04 | 103 | 8 | 2 | CID000019654 | |
| Drug | Reserpine | 7.43e-04 | 119 | 8 | 2 | ctd:D012110 | |
| Drug | kaempferol | 1.16e-03 | 149 | 8 | 2 | ctd:C006552 | |
| Drug | LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 1.71e-03 | 181 | 8 | 2 | 1077_UP | |
| Drug | Dicumarol [66-76-2]; Down 200; 11.8uM; PC3; HT_HG-U133A | 1.82e-03 | 187 | 8 | 2 | 4323_DN | |
| Drug | troglitazone; Up 200; 10uM; PC3; HG-U133A | 1.88e-03 | 190 | 8 | 2 | 462_UP | |
| Drug | Ticlopidine hydrochloride [53885-35-1]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 1.88e-03 | 190 | 8 | 2 | 4155_UP | |
| Drug | Sulfamethazine sodium salt [1981-58-4]; Down 200; 13.4uM; PC3; HT_HG-U133A | 1.88e-03 | 190 | 8 | 2 | 4322_DN | |
| Drug | Proglumide [6620-60-6]; Up 200; 12uM; MCF7; HT_HG-U133A | 1.90e-03 | 191 | 8 | 2 | 3861_UP | |
| Drug | Solasodine [126-17-0]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 1.90e-03 | 191 | 8 | 2 | 3830_UP | |
| Drug | Ethynodiol diacetate [297-76-7]; Up 200; 10.4uM; PC3; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 6678_UP | |
| Drug | 15d-PGJ2; Up 200; 10uM; MCF7; HG-U133A | 1.94e-03 | 193 | 8 | 2 | 201_UP | |
| Drug | Remoxipride Hydrochloride [73220-03-8]; Down 200; 9.8uM; HL60; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 3124_DN | |
| Drug | Naltrexone hydrochloride dihydrate [16676-29-2]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 2209_UP | |
| Drug | Fluoxetine hydrochloride [59333-67-4]; Up 200; 11.6uM; PC3; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 6757_UP | |
| Drug | AG-013608 [351320-38-2]; Down 200; 10uM; PC3; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 6400_DN | |
| Drug | Minocycline hydrochloride [13614-98-7]; Up 200; 8uM; PC3; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 5077_UP | |
| Drug | chlorpromazine hydrochloride; Up 200; 1uM; PC3; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 4441_UP | |
| Drug | Dubinidine [22964-77-8]; Up 200; 14.6uM; PC3; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 5774_UP | |
| Drug | Fluspirilen [1841-19-6]; Up 200; 8.4uM; PC3; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 6662_UP | |
| Drug | Amiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; PC3; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 4657_UP | |
| Drug | Protriptyline hydrochloride [1225-55-4]; Down 200; 13.4uM; HL60; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 3119_DN | |
| Drug | Finasteride [98319-26-7]; Up 200; 10.8uM; PC3; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 4300_UP | |
| Drug | genistein; Down 200; 1uM; MCF7; HG-U133A | 1.98e-03 | 195 | 8 | 2 | 268_DN | |
| Drug | radicicol; Down 200; 0.1uM; MCF7; HG-U133A | 1.98e-03 | 195 | 8 | 2 | 489_DN | |
| Drug | cox-2 inhibitor I; Up 200; 10uM; MCF7; HG-U133A | 1.98e-03 | 195 | 8 | 2 | 207_UP | |
| Drug | Palmatine chloride [3486-67-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 2795_UP | |
| Drug | Meclofenamic acid sodium salt monohydrate [6385-02-0]; Down 200; 11.8uM; HL60; HG-U133A | 2.00e-03 | 196 | 8 | 2 | 1445_DN | |
| Drug | Sulfamethoxazole [723-46-6]; Up 200; 15.8uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 2335_UP | |
| Drug | Crotamiton [483-63-6]; Up 200; 19.6uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 5689_UP | |
| Drug | Methylprednisolone, 6-alpha [83-43-2]; Down 200; 10.6uM; HL60; HG-U133A | 2.00e-03 | 196 | 8 | 2 | 1567_DN | |
| Drug | Estrone [53-16-7]; Up 200; 14.8uM; PC3; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 6647_UP | |
| Drug | PNU-0230031 [267429-39-0]; Up 200; 1uM; PC3; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 4291_UP | |
| Drug | Domperidone maleate; Down 200; 7.4uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 1301_DN | |
| Drug | Quinidine hydrochloride monohydrate [6151-40-2]; Up 200; 10.6uM; PC3; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 5793_UP | |
| Drug | Dibucaine [85-79-0]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 4149_UP | |
| Drug | Bemegride [64-65-3]; Down 200; 25.8uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 3389_DN | |
| Drug | Sulindac [38194-50-2]; Down 200; 11.2uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 1857_DN | |
| Drug | Methylhydantoin-5-(D) [55147-68-7]; Up 200; 35uM; PC3; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 3994_UP | |
| Drug | Amyleine hydrochloride [532-59-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 4169_UP | |
| Drug | Iodixanol [92339-11-2]; Up 200; 2.6uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 3362_UP | |
| Drug | Guanadrel sulfate [22195-34-2]; Up 200; 7.6uM; PC3; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 3698_UP | |
| Drug | Riluzole hydrochloride; Up 200; 14.8uM; PC3; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 3666_UP | |
| Drug | Cefaclor [70356-03-5]; Up 200; 10.4uM; PC3; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 6622_UP | |
| Drug | Dantrolene sodium salt [14663-23-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 3978_UP | |
| Drug | Triamcinolone [124-94-7]; Up 200; 10.2uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 2241_UP | |
| Drug | Debrisoquin sulfate [581-88-4]; Up 200; 9uM; PC3; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 6688_UP | |
| Drug | Methacholine chloride [62-51-1]; Up 200; 20.4uM; PC3; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 5773_UP | |
| Drug | 17-AAG; Down 200; 1uM; MCF7; HG-U133A | 2.02e-03 | 197 | 8 | 2 | 381_DN | |
| Drug | Penbutolol sulfate [38363-32-5]; Up 200; 5.8uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 7476_UP | |
| Drug | Carisoprodol [78-44-4]; Down 200; 15.4uM; HL60; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 1314_DN | |
| Drug | Benperidol [2062-84-2]; Up 200; 10.4uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 2836_UP | |
| Drug | Isometheptene mucate; Up 200; 8.2uM; PC3; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 5082_UP | |
| Drug | S(-)-terguride hydrogen maleate [37686-85-4]; Up 200; 8.8uM; MCF7; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 5694_UP | |
| Drug | Famotidine [76824-35-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 1529_UP | |
| Drug | ICI 182,780; Up 200; 0.01uM; PC3; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 4462_UP | |
| Drug | Thalidomide [50-35-1]; Down 200; 15.4uM; HL60; HG-U133A | 2.04e-03 | 198 | 8 | 2 | 1411_DN | |
| Drug | Cephalexin monohydrate [23325-78-2]; Up 200; 11uM; MCF7; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 5615_UP | |
| Drug | Hyoscyamine (L) [101-31-5]; Up 200; 13.8uM; PC3; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 2108_UP | |
| Drug | Vitexin [3681-93-4]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 4413_UP | |
| Drug | Quinethazone [73-49-4]; Down 200; 13.8uM; PC3; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 3793_DN | |
| Drug | Niridazole [61-57-4]; Up 200; 18.6uM; PC3; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 4621_UP | |
| Drug | Propranolol hydrochloride [318-98-9]; Up 200; 13.6uM; MCF7; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 3396_UP | |
| Drug | sodium 4-phenylbutyrate; Up 200; 1000uM; MCF7; HG-U133A | 2.06e-03 | 199 | 8 | 2 | 408_UP | |
| Drug | Niacin [59-67-6]; Down 200; 32.4uM; MCF7; HT_HG-U133A | 2.06e-03 | 199 | 8 | 2 | 3381_DN | |
| Drug | Proglumide [6620-60-6]; Up 200; 12uM; PC3; HT_HG-U133A | 2.06e-03 | 199 | 8 | 2 | 4337_UP | |
| Drug | S(+)-Terguride [37686-84-3]; Down 200; 11.8uM; HL60; HT_HG-U133A | 2.06e-03 | 199 | 8 | 2 | 3082_DN | |
| Drug | Ofloxacin [82419-36-1]; Up 200; 11uM; MCF7; HT_HG-U133A | 2.06e-03 | 199 | 8 | 2 | 2302_UP | |
| Drug | sulindac sulfone; Down 200; 50uM; MCF7; HG-U133A | 2.06e-03 | 199 | 8 | 2 | 314_DN | |
| Drug | 3-aminobenzamide; Down 200; 10000uM; MCF7; HG-U133A | 2.06e-03 | 199 | 8 | 2 | 590_DN | |
| Drug | Hydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; HL60; HG-U133A | 2.06e-03 | 199 | 8 | 2 | 2024_DN | |
| Drug | Proparacaine hydrochloride [5875-06-9]; Up 200; 12uM; MCF7; HT_HG-U133A | 2.06e-03 | 199 | 8 | 2 | 5433_UP | |
| Drug | Dorzolamide hydrochloride [130693-82-2]; Up 200; 11uM; PC3; HT_HG-U133A | 2.06e-03 | 199 | 8 | 2 | 5785_UP | |
| Drug | retinoic acid; Down 200; 1uM; MCF7; HG-U133A | 2.06e-03 | 199 | 8 | 2 | 384_DN | |
| Drug | Flunisolide [3385-03-3]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 2.08e-03 | 200 | 8 | 2 | 6023_UP | |
| Disease | myocardial infarction (is_implicated_in) | 3.08e-04 | 99 | 8 | 2 | DOID:5844 (is_implicated_in) | |
| Disease | Acute Myeloid Leukemia, M1 | 4.90e-04 | 125 | 8 | 2 | C0026998 | |
| Disease | Acute Myeloid Leukemia (AML-M2) | 4.90e-04 | 125 | 8 | 2 | C1879321 | |
| Disease | Leukemia, Myelocytic, Acute | 9.35e-04 | 173 | 8 | 2 | C0023467 | |
| Disease | central corneal thickness | 2.94e-03 | 309 | 8 | 2 | EFO_0005213 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| FFKLSAYGKHFHLNL | 86 | Q9UKP5 | |
| AINGKYHRFLGRHFP | 66 | Q6P1Q0 | |
| HRHKFLPERYPDKGF | 241 | P14210 | |
| GAKHCRNYKFRFHKP | 3736 | Q03164 | |
| GLAFHPKFRHNRKFY | 276 | Q6UWX4 | |
| KFRSKHYFSKHPQRG | 676 | Q13474 | |
| IIFHAGYSLKKRHFF | 191 | Q96T83 | |
| LYHFYHNGLAKAKRR | 66 | P16519 |